http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005298424-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_650add86168b1a60eb53f021958927c2
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01D9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-36
filingDate 2004-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db94660f90ecc50283c6c588c253c042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_600747811d3b0d2044316fe25665545b
publicationDate 2005-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2005298424-A
titleOfInvention Method for producing epalrestat crystals
abstract The present invention relates to a method for efficiently and easily producing epalrestat B-type crystals having a single crystal form with high solubility, and a pharmaceutical composition containing the single crystal form of epalrestat crystals obtained by the production method of the present invention. To provide things. A method for producing epalrestat crystals, wherein epalrestat is dissolved in methanol, and then the resulting solution is cooled and crystallized, and a pharmaceutical comprising epalrestat crystals obtained by the production method Composition. [Selection figure] None
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-023435-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10464912-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010028132-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8697735-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-016904-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114456125-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103951634-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115925650-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9566269-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105272934-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108191788-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102977047-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9447056-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108191788-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8906948-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114456125-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2476202-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2476202-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107629021-A
priorityDate 2004-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19096565
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID2750
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410693820
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226432889
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1549120
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448510434
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226432890
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411161974
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449603119
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416129752
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3015105
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1584822
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID887
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID751
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419517688
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411932836
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6594
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID2750

Total number of triples: 52.